The College of American Pathologists has updated 14 Cancer Protocols, mandating the Breast Phyllodes Tumor protocol for accreditation and revising breast biomarker and GIST molecular testing criteria, according to CAP.
The diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.
The tool uses digitized pathology slides to estimate how patients will respond to therapy before surgery.
A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Read More
Three abstracts showcase PreciseBreast’s ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.
Read More
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More
The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.
Read More
A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.
Read More
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Read More
The research‑use‑only test for post‑treatment breast cancer monitoring is now available through the company’s affiliate EG Biomed US.
Read More
The agreement focuses on clinical validation of ESR1 mutation detection assay for advanced breast cancer testing using ddPCR technology.
Read More
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
Read More
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
Read More
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read More
Personalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read More
SAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read More
Hologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read More
A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read More